No, Adalimumab Biosimilars Are NOT Biosimilar to Nivolumab
Adalimumab biosimilars (adalimumab-atto, adalimumab-adbm) are biosimilars of adalimumab (Humira), not nivolumab (Opdivo). These are completely different drugs with different mechanisms of action, different indications, and different molecular structures.
Key Distinctions
Different Drug Classes and Mechanisms
- Adalimumab and its biosimilars are anti-TNF-alpha (tumor necrosis factor) monoclonal antibodies used to treat inflammatory and autoimmune conditions 1, 2
- Nivolumab is an anti-PD-1 (programmed death-1) monoclonal antibody used as an immunotherapy for cancer 3
What "Biosimilar" Actually Means
A biosimilar is a biological product that is highly similar to an FDA-approved reference product with no clinically meaningful differences in safety, purity, or potency 1, 2. The biosimilar relationship is specific:
- Adalimumab-adbm (Cyltezo) is biosimilar to Humira (adalimumab) 1
- Adalimumab-atto (Amjevita) is biosimilar to Humira (adalimumab) 2
- Neither has any relationship to nivolumab
Approved Indications Differ Completely
Adalimumab biosimilars treat inflammatory conditions 1, 2:
- Rheumatoid arthritis
- Psoriatic arthritis
- Crohn's disease
- Ulcerative colitis
- Plaque psoriasis
- Hidradenitis suppurativa
- Non-infectious uveitis
Nivolumab treats malignancies (not listed in adalimumab labels).
Common Pitfall to Avoid
Do not confuse the concept of "biosimilar to biosimilar switching" (switching between different biosimilars of the same reference product, like switching from adalimumab-atto to adalimumab-adbm) 4 with the erroneous notion that biosimilars of different reference products are interchangeable. Adalimumab biosimilars can only be switched among themselves or with reference adalimumab—never with nivolumab or its biosimilars.